Advertisement

Management of Acute Myocardial Infarction

Part of the Contemporary Cardiology book series (CONCARD)

Abstract

Acute coronary syndrome (ACS) embraces ST-segment-elevation myocardial infarction (STEMI) and non-ST-elevation MI (NSTEMI)-ACS (1). The terms Q-wave and non-Q-wave MI are no longer used. Patients presenting with NSTEMIACS symptoms without biochemical markers of acute myocardial infarction (AMI) (particularly elevated troponin) are regarded as having unstable angina (Fig. 11).

Keywords

Percutaneous Coronary Intervention Acute Coronary Syndrome Acute Myocardial Infarction Acute Myocardial Infarction Thrombolytic Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hamm CW, Bertrand M, Braunwald E. Acute coronary syndrome without ST elevation: Implementation of new guidelines. Lancet 2001;358:1533.PubMedCrossRefGoogle Scholar
  2. 2.
    Thuresson M, Jarlov MB, Lindahl B, et al. Symptoms and type of symptom onset in acute coronary syndrome in relation to ST elevation, sex, age, and a history of diabetes. Am Heart J 2005; 150:234–242.PubMedCrossRefGoogle Scholar
  3. 3.
    Topol EJ. The genomic basis of myocardial infarction. J Am Coll Cardiol 2005;46:1456–1465.PubMedCrossRefGoogle Scholar
  4. 4.
    American Heart Association: Heart Facts 2005. All Americans. Available at: http://www.americanheart.org/downloadable/heart/1106668161495AllAmAfAmHeartFacts05.pdf. Accessed July 27, 2005.
  5. 5.
    Willett WC. Balancing life-style and genomics research for disease prevention Science 2002;296: 695–698.PubMedCrossRefGoogle Scholar
  6. 6.
    Wang Q, Rao S, Shen G-Q, et al. Premature myocardial infarction novel susceptibility locus on chromosome lp34-36 identified by genome-wide linkage analysis Am J Hum Genet 2004;74:262–271.PubMedCrossRefGoogle Scholar
  7. 7.
    Topol EJ, McCarthy J, Gabriel S, et al. GeneQuest Investigators. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction Circulation 2001; 104:2641–2644.PubMedCrossRefGoogle Scholar
  8. 8.
    DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897.CrossRefGoogle Scholar
  9. 9.
    ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither, among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:350.Google Scholar
  10. 10.
    Randomized trial. The OASIS-6 Trial Group. JAMA 2006;295:1519–1530.CrossRefGoogle Scholar
  11. 11.
    CAPRICORN Investigators. Effect of carvedilol on outcome after MI in patients with left ventricular dysfunction; the CAPRICORN randomized trial. Lancet 2001;357:1385–1390.CrossRefGoogle Scholar
  12. 12.
    Ambrosioni E, Borghi C, Magnani B, et al. for the Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 1995;332:80.PubMedCrossRefGoogle Scholar
  13. 13.
    Pfeffer MA, Braunwald E, Moye LA, et al. for the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992;327:669.PubMedCrossRefGoogle Scholar
  14. 14.
    Vantrimpont P, Roleau JL, Chaun-Chaun W, et al. Additive beneficial effects of beta-blockers to angiotensin converting enzyme inhibitors in Survival and Ventricular Enlargement (SAVE) study. J Am Coll Cardiol 1997;29:229.PubMedCrossRefGoogle Scholar
  15. 15.
    Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction—executive summary. J Am Coll Cardiol 2004;44:671–719.PubMedCrossRefGoogle Scholar
  16. 16.
    GISSI: Italian Group. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397.Google Scholar
  17. 17.
    ISIS Steering Committee. Intravenous streptokinase given within 0–4 h of onset of myocardial infarction reduced mortality in ISIS-2. Lancet 1987;l:501.Google Scholar
  18. 18.
    Sheehan FH, Braunwald E, Canner P, et al. The effect of intravenous thrombolytic therapy on left ventricular function: A report on tissue-type plasminogen activator and streptokinase from the thrombolysis in myocardial infarction (TIMI phase I) trial. Circulation 1987;75:817.PubMedGoogle Scholar
  19. 19.
    GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673.CrossRefGoogle Scholar
  20. 20.
    ASSENT-2 Investigators. Assessment of the Safety and Efficacy of a New Thrombolytic: Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomized trial. Lancet 1999;354:716.CrossRefGoogle Scholar
  21. 21.
    Collins R, Peto R, Baigent C, et al. Aspirin, heparin and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997;336:847.PubMedCrossRefGoogle Scholar
  22. 22.
    Thiemann DR, Coresh J, Schulman SP, et al. Lack of benefit for IV thrombolysis in patients with MI who are older than 75 years. Circulation 2000;101:2239.PubMedGoogle Scholar
  23. 23.
    INJECT: International Joint Efficacy Comparison of Thrombolytics. Randomized, double blind comparison of reteplase-double bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet 1995;46:329.Google Scholar
  24. 24.
    Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118.CrossRefGoogle Scholar
  25. 25.
    Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction for the ExTRACT-TIMI 25 Investigators. N Engl J Med 2006; 354:1477–1488.PubMedCrossRefGoogle Scholar
  26. 26.
    The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006;354:1464–1476.CrossRefGoogle Scholar
  27. 27.
    MIAMI Trial Research Group. Metoprolol in acute MI (MIAMI): A randomized placebo-controlled international trial. Eur Heart J 1985;6:199.Google Scholar
  28. 28.
    ISIS-1 Group. Randomized trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 1986;2:57.Google Scholar
  29. 29.
    Khan M Gabriel. Which beta blocker to choose. In: Heart Disease Diagnosis and Therapy, 2nd ed. Totowa, NJ, Humana Press, 2005, p. 55.Google Scholar
  30. 30.
    International Collaborative Study Group. Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med 1984;310:9.CrossRefGoogle Scholar
  31. 31.
    Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute MI. N Engl J Med 1981;304:801.CrossRefGoogle Scholar
  32. 32.
    Beta-blocker heart attack study group (BHAT). The Beta Blocker Heart Attack Trial. JAMA 1981;246: 2073.CrossRefGoogle Scholar
  33. 33.
    Fourth International Study of Infarct Survival Collaborative Group. A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345:669.CrossRefGoogle Scholar
  34. 34.
    Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–1504.PubMedCrossRefGoogle Scholar
  35. 35.
    Scirica BM, Morrow DA, Cannon CP, for the PROVE IT-TIMI22 Investigators. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 Study. J Am Coll Cardiol 2006;47:2326–2331.PubMedCrossRefGoogle Scholar
  36. 36.
    Woods KL, Fletcher S, Roffe C, et al. Intravenous magnesium sulphate in suspected acute myocardial infarction: Results of the Second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992;339:1553.PubMedCrossRefGoogle Scholar
  37. 37.
    Woods KL, Fletcher S. Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: The Second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1994;343:816.PubMedCrossRefGoogle Scholar
  38. 38.
    Bowli R. Mechanism of myocardial “stunning.” Circulation 1990;82:723.Google Scholar
  39. 39.
    MAGIC Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: A randomized controlled trial. Lancet 2002;360:1189.CrossRefGoogle Scholar
  40. 40.
    Lawrie DM, Higgins MR, Godman MJ, et al. Ventricular fibrillation complicating acute myocardial infarction. Lancet 1968;2:523.PubMedCrossRefGoogle Scholar
  41. 41.
    Adgey AAJ, Geddes JS, Mulholland HC, et al. Incidence, significance, and management of early bradyarrhythmia complicating acute myocardial infarction. Lancet 1968;2:1097.PubMedGoogle Scholar
  42. 42.
    Warren JV, Lewis RP. Beneficial effects of atropine in the pre-hospital phase of coronary care. Am J Cardiol 1976;37:68.PubMedCrossRefGoogle Scholar
  43. 43.
    Massumi RA, Mason DT, Amsterdam EA, et al. Ventricular fibrillation and tachycardia after intravenous atropine for treatment of bradycardias. N Engl J Med 1972;287:336.PubMedCrossRefGoogle Scholar
  44. 44.
    Wellens HJJ. Right ventricular infarction. N Engl J Med 1993;328:1036.PubMedCrossRefGoogle Scholar
  45. 45.
    Zehender M, Casper W, Kauder E, et al. Right ventricular infarction as an independent predictor of prognosis after acute inferior myocardial infarction. N Engl J Med 1993;328:981.PubMedCrossRefGoogle Scholar
  46. 46.
    Hurst JW. Right ventricular infarction. N Engl J Med 1994;331:681.PubMedCrossRefGoogle Scholar
  47. 47.
    Kinch JW, Ryan TJ. Right ventricular infarction. N Engl J Med 1994;17:1211.CrossRefGoogle Scholar
  48. 48.
    Cotter G, Kaluski E, Blatt A, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation 2000;101:1358.PubMedGoogle Scholar
  49. 49.
    Hochman JS, Sleeper LA, Webb JG, et al. forthe SHOCK investigators. Early revascularization in acute MI complicated by cardiogenic shock: Should we emergently revascularize occluded coronaries for cardiogenic shock? N Engl J Med 1999;341:625.PubMedCrossRefGoogle Scholar
  50. 50.
    Hochman JS, Sleper LA, White HD. One year survival following early revascularization for cardiogenic shock JAMA 2001;285:190–192.PubMedCrossRefGoogle Scholar
  51. 51.
    Ray KK, Cannon CP, Cairns R, et al. for the PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: Results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005;46:1405–1410.PubMedCrossRefGoogle Scholar
  52. 52.
    Topol EA, Moliterno DJ, Hermann HC, et al. forthe TARGET investigators. Comparison of two platelet glycoprotein Ilb/IIIa inhibitors, tirofiban and abciximab for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888.PubMedCrossRefGoogle Scholar
  53. 53.
    Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein Ilb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879.PubMedCrossRefGoogle Scholar
  54. 54.
    Roffi M, Chew P, Mukherjee D, et al. Platelet glycoprotein Ilb/IIIa inhibitors reduce mortality in diabetic patients with non ST segment elevation acute coronary syndromes. Circulation 2001; 104:2767.PubMedCrossRefGoogle Scholar
  55. 55.
    Sabatine MS, Braunwald E. Will diabetes save the platelet blockers? Circulation 2001;104:2759.PubMedGoogle Scholar
  56. 56.
    The Clopidogrel in Unstable Angina to Prevent Recurrent Events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. N Engl J Med 2001;345:494.CrossRefGoogle Scholar
  57. 57.
    Mehta S, Yusuf S, Peters R, et al. Effects of pre-treatment with clopidogrel and aspirin followed by longterm therapy in patients undergoing percutaneous coronary intervention. The PCI-CURE study. Lancet 2001;358:527–533.PubMedCrossRefGoogle Scholar
  58. 58.
    Steinhubl SR, Charnigo R, Topol EJ. Clopidogrel treatment prior to percutaneous coronary intervention: When enough isn’t enough. JAMA 2006;295:1581–1582.PubMedCrossRefGoogle Scholar
  59. 59.
    Giugliano RP, Braunwald E. The year in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2005;46:906–919.PubMedCrossRefGoogle Scholar
  60. 60.
    Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention Circulation 2005;lll:2560–2564.CrossRefGoogle Scholar
  61. 61.
    Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention. Results from the ARMYDA-2 (Antiplatelet Therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005;111:2099–2106.PubMedCrossRefGoogle Scholar
  62. 62.
    Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions: The task force for percutaneous coronary interventions of the European Society of Cardiology. Eur Heart J 2005;26: 804–847.PubMedCrossRefGoogle Scholar
  63. 63.
    Stone GW. Acute Catheterization and Urgent Intervention Triage Strategy Trial (ACUITY). Presented at the 2006 ACC Annual Scientific Session, Mar 11–14, 2006, Atlanta, GA.Google Scholar
  64. 64.
    Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI2005 guideline update forpercutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006;47:el–121.Google Scholar

Suggested Reading

  1. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction for the ExTRACT-TIMI 25 Investigators. N Engl J Med 2006; 354:1477–1488.PubMedCrossRefGoogle Scholar
  2. Bavry AA, Lincoff AM. Is clopidogrel cardiovascular medicine’s double-edged sword? Circulation 2006; 113:1638–1640.PubMedCrossRefGoogle Scholar
  3. Beygui F, Collet J-P, Benoliel J-J, et al. High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 2006; 114:2604–2610.PubMedCrossRefGoogle Scholar
  4. Calhoun DA. Aldosterone and cardiovascular disease: Smoke and fire. Circulation 2006;114:2572–2574.PubMedCrossRefGoogle Scholar
  5. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 2004;350:1495–1504.PubMedCrossRefGoogle Scholar
  6. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159–168.PubMedCrossRefGoogle Scholar
  7. Giugliano RP, Braunwald E. The year in non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2006;48:386–395.PubMedCrossRefGoogle Scholar
  8. Hirsch A, Windhausen F, Tijssen JGP for the Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) investigators. Long-term outcome after an early invasive versus selective invasive treatment strategy in patients with non-ST-elevation acute coronary syndrome and elevated cardiac troponin T (the ICTUS trial): a follow-up study. Lancet 2007;369:827–835.PubMedCrossRefGoogle Scholar
  9. Hockman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. J Engl J Med 2006;355:2395–2407.CrossRefGoogle Scholar
  10. Randomized Trial. The OASIS-6 Trial Group. JAMA 2006;295:1519–1530.CrossRefGoogle Scholar
  11. Remme WJ, Torp-Pedersen C, Cleland JGF, et al. Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. J Am Coll Cardiol 2007; 49:963–971.PubMedCrossRefGoogle Scholar
  12. Scirica BM, Morrow DA, Cannon CP, et al. for the PROVE IT-TIMI22 Investigators. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol 2006;47:2326–2331.PubMedCrossRefGoogle Scholar
  13. Scirica BM, Sabatine MS, Morrow DA, et al. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction. The ECG CLARITY-TIMI28 study. J Am Coll Cardiol 2006;48:37–42.PubMedCrossRefGoogle Scholar
  14. Stevens LA, Coresh J, Greene T. Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 2006;354:2473–2483.PubMedCrossRefGoogle Scholar
  15. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203–2216.PubMedCrossRefGoogle Scholar
  16. Van Melle JP, Verbeek DEP, van den Berg MP, et al. Beta-blockers and depression after myocardial infarction: a multicenter prospective study. J Am Coll Cardiol 2006;48:2209–2214.PubMedCrossRefGoogle Scholar
  17. Von Känel, BS. Depression after myocardial infarction: Editorial. Unraveling the mystery of poor cardiovascular prognosis and role of beta-blocker therapy. J Am Coll Cardiol 2006;48:2215–2217.CrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2007

Personalised recommendations